FLT3 TriTAC-XR

N/A

Report date: 2026/03/19 16:57:39

Base Information

Drug NameFLT3 TriTAC-XR
Drug Alias NameAnti-CD3/anti-FLT3/anti-albumin trispecific T-cell engager (Harpoon Therapeutics)Anti-CD3/anti-FLT3/anti-albumin trispecific T-cell engager (Harpoon Therapeutics)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsProtease modulatorsSerum albumin modulators +[4] 
TargetsT cell surface glycoprotein CD3Tyrosine-protein kinase receptor FLT3Serum albumin +[4] 
Therapy Area/IndicationsSolid tumoursHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesHarpoon Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMerck & Co Inc
Inactive CompaniesHarpoon Therapeutics Inc
Active IndicationsSolid tumoursHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A